|
|
|
|
||
CytomX Therapeutics Announces Technology Acquisition From Agensys, Inc.Today's acquiring drug conjugate linker-toxin and CD3-based bispecific technologies indicates Probody clinical trial interim data from CX-072, CX-2009 further moving along, CX-2009 initial data release in Jun 2019 is just 5 months away... |
return to message board, top of board |